Indehaveren af markedsføringstilladelsen pegede på muligheden af fluoxetin- induceret hæmning af GnRH som en årsag til forstyrrelse af det endokrine system.
The MAH suggested the involvement of fluoxetine-induced inhibition of GnRH, so that fluoxetine would act as an endocrine disrupter.